Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line osimertinib for poor performance status EGFR-mutant non-small cell lung cancer
jRCTs041200100Completed
- Sponsor
- Japan Thoracic Oncology Research Group
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Japan Thoracic Oncology Research Group. Primary endpoint: Objective response rate. Started Feb 2021; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs041200100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041200100.